1-7 of 7
Ju-hee Bang
Close
Sort by
Journal Articles

Comparison of Sokal, Hasford and EUTOS Scores in Terms of Long-Term Treatment Outcome According to the Risks in Each Prognostic Model: A Single Center Data Analyzed in 255 Early Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib Mesylate.

Seung-Ah Yahng, Eun-Jung Jang, Soo Young Choi, Yun-Jung Oh, Ju-Hee Bang, Jin-Eok Park, Hye-Lim Jeon, Sung-Eun Lee, Soo-Hyun Kim, Ji-Young Byun, Dong-Wook Kim
Journal: Blood
Blood (2012) 120 (21): 2794.
https://doi.org/10.1182/blood.V120.21.2794.2794
Published: 2012
Journal Articles

Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study

Soo-Young Choi, Sung-Eun Lee, Soo-Hyun Kim, Eun-Jung Jang, Jin-hwa Lee, Yun-Jung Oh, Ju-Hee Bang, Jin-Eok Park, Ji-Young Byun, Hye-Lim Jeon, Richard C. Woodman, Tomasz Szczudlo, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung-Hyun Kim, Dae-Young Zang, Suk-Joong Oh, Dong-Wook Kim
Journal: Blood
Blood (2012) 120 (21): 3775.
https://doi.org/10.1182/blood.V120.21.3775.3775
Published: 2012
Journal Articles

Dynamics and Characteristics of BCR-ABL1 Multiple Mutations in Tyrosine Kinase Inhibitor Resistant CML

Soo-Hyun Kim, Soo Young Choi, Sung-Eun Lee, Ju-Hee Bang, Ji-Young Byeun, Jin-Eok Park, Hye-Rim Jeon, Eun-Jung Jang, Saengsuree Jootar, Dong-Wook Kim
Journal: Blood
Blood (2012) 120 (21): 1677.
https://doi.org/10.1182/blood.V120.21.1677.1677
Published: 2012
Journal Articles

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

Clinical Trials & Observations
Susan Branford, David T. Yeung, Jodi A. Prime, Soo-Young Choi, Ju-hee Bang, Jin Eok Park, Dong-Wook Kim, David M. Ross, Timothy P. Hughes
Journal: Blood
Blood (2012) 119 (18): 4264–4271.
https://doi.org/10.1182/blood-2011-11-393041
Published: 2012
Includes: Supplemental data
Journal Articles

Discontinuation of Imatinib Therapy in Chronic Myeloid Leukemia Patients with Sustained Complete Molecular Response 4.5 (CMR 4.5 )

Hyun-Gyung Goh, Soo-Young Choi, Ju-Hee Bang, Soo-Hyun Kim, Eun-Jung Jang, Dongho Kim, Ji-Young Byeun, Joon Seong Park, Hyeoung-Joon Kim, Hawk Kim, Dong-Wook Kim
Journal: Blood
Blood (2011) 118 (21): 2763.
https://doi.org/10.1182/blood.V118.21.2763.2763
Published: 2011
Journal Articles

Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study)

Hyun-Gyung Goh, Saengsuree Jootar, Hyeoung-Joon Kim, Sang Kyun Sohn, Joon Seong Park, Sung Hyun Kim, Dae Young Zang, Suk-Joong Oh, Soo-Young Choi, Ju-Hee Bang, Soo-Hyun Kim, Eun-Jung Jang, Sung-Eun Lee, Dongho Kim, Ji-Young Byeun, Richard C. Woodman, Tomasz Szczudlo, Hee Jung Kim, Dong-Wook Kim
Journal: Blood
Blood (2011) 118 (21): 2765.
https://doi.org/10.1182/blood.V118.21.2765.2765
Published: 2011
Journal Articles

Correlation of Molecular Response At 18 Month with Survival Benefits As Response-Related Prognostic Factor

Soo-Hyun Kim, Dongho Kim, Hyun-Gyung Goh, Soo-Young Choi, Ju-Hee Bang, Ji-Young Byeun, Dong-Wook Kim
Journal: Blood
Blood (2011) 118 (21): 2766.
https://doi.org/10.1182/blood.V118.21.2766.2766
Published: 2011